Dey, Esha

Follow Dey, Esha: Website |


New obesity drug won’t target your hunger, but it will target your fat

New obesity drug won’t target your hunger, but it will target your fat

August 26, 2013 9:41 am by | 0 Comments

(Reuters) – Imagine a weight-loss drug that not only helps you shed a few pounds, but does so without asking you to diet or exercise. In an industry dogged by…


Shares drop for Regeneron as eye drug sales slow in second quarter

Shares drop for Regeneron as eye drug sales slow in second quarter

August 7, 2013 2:31 am by | 0 Comments

(Reuters) – The explosive growth in the sales of Regeneron Pharmaceuticals Inc’s Eylea eye drug slowed in the second quarter as existing patients moved to less-frequent dosing.
Shares of Regeneron fell 6.1 percent on Tuesday even though the company sa…



Is Alynlam the next breakthrough name in biotechnology? Investors say ‘yes’

Is Alynlam the next breakthrough name in biotechnology? Investors say ‘yes’

July 12, 2013 10:47 am by | 0 Comments

(Reuters) – A radical new treatment for genetic disorders has catapulted Alnylam Pharmaceuticals Inc into the crosshairs of investors seeking the next breakthrough name in biotechnology.
The challenge for the Cambridge, Massachusetts-based company now…


Dendreon’s cancer vaccine sales drop as competition heats up

Dendreon’s cancer vaccine sales drop as competition heats up

May 9, 2013 10:55 am by | 0 Comments

(Reuters) – Sales of Dendreon Corp’s prostate cancer vaccine Provenge declined in the first quarter despite efforts by the biotechnology drugs maker to shore up flagging volumes.
The company’s shares fell 14 percent to $4.06 in morning trade on the Na…


Exact Sciences cancer test meets goal, but disappoints investors

Exact Sciences cancer test meets goal, but disappoints investors

April 18, 2013 10:01 am by | 0 Comments

(Reuters) – Exact Sciences Corp said its molecular screening test for colorectal cancer met its goals in a large late-stage study, detecting the disease in more than 90 percent of patients, but its shares plummeted 30 percent on Thursday as the result…


FDA extends review of Biogen’s multiple sclerosis drug

FDA extends review of Biogen’s multiple sclerosis drug

October 18, 2012 5:32 pm by | 0 Comments

(Reuters) – Biotechnology company Biogen Idec Inc said U.S. health regulators extended by three months the review date of its much-awaited multiple sclerosis (MS) drug BG-12, but analysts said the delay was only a minor setback.
Shares of Biogen were …


FDA reviewers say Sanofi, Isis lipid drug may increase the risk of cancer

FDA reviewers say Sanofi, Isis lipid drug may increase the risk of cancer

October 16, 2012 2:51 pm by | 0 Comments

(Reuters) – U.S. drug reviewers flagged several safety concerns, including possible cancer risks, related to Sanofi SA and Isis Pharmaceuticals Inc’s lipid disorder drug Kynamro, sending Isis’s shares down as much as 21 percent.
In briefing documents …